Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Down 7.2% – Here’s What Happened

Posted by Stanley Muller on Sep 14th, 2026

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) traded down 7.2% during trading on Monday . The stock traded as low as $44.1979 and last traded at $44.1979. Approximately 275 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 2,766 shares. The stock had previously closed at $47.64.

Analyst Upgrades and Downgrades

ZLDPF has been the subject of several research reports. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Barclays downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Get Our Latest Analysis on Zealand Pharma A/S

Zealand Pharma A/S Stock Performance

The firm has a fifty day simple moving average of $47.50 and a 200-day simple moving average of $47.10. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of 7.33 and a beta of 0.89.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience.

Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes.